GLP-1 receptor agonists demonstrate potential beyond glucose control, showing reduced atrial fibrillation risk and recurrence rates in observational studies and meta-analyses. These medications appear to interrupt the obesity-AF cycle through anti-inflammatory effects, oxidative stress reduction, decreased epicardial fat, and reduced atrial fibrosis—addressing the root mechanisms that create proarrhythmic substrates. This represents a significant evolution in AF prevention strategy. The obesity-AF connection operates through well-established pathways: systemic inflammation, structural atrial remodeling, and hemodynamic changes that promote arrhythmia initiation and maintenance. Weight loss has long shown benefits for AF burden, but achieving sustained weight reduction remains challenging for most patients. GLP-1 agonists offer a pharmacological approach that could make meaningful AF prevention accessible to broader populations. However, the evidence base remains preliminary. Most data comes from studies where AF was a secondary endpoint, limiting the strength of conclusions. The field urgently needs dedicated randomized controlled trials with AF as the primary outcome, standardized monitoring protocols, and extended follow-up periods to establish whether these promising signals translate into clinically meaningful arrhythmia prevention.